HN
Hangzhou Tigermed Consulting Co., Ltd
HNGZY · OTC
$4.45 +0.00% (+$0.00)
Market Cap ¥45.9B
P/E Ratio 495.14x
Div. Yield 0.41%
ROE 0.45%
Bulios Fair Price
$2.64
40.7% downside
Current Price
$4.45
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HNGZY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
27 /100
Expensive P/E 495.14x
PEG 0.43x
EV/EBITDA 25.66x
Growth
15 /100
Declining EPS growth 23.47%
Book val. growth 2.29%
Rev. growth 1.20%
Profitability
50 /100
Moderate Gross margin 25.85%
FCF margin 16.36%
Net margin 1.27%
Quality
5 /100
Poor ROIC 1.20%
Asset turnover 0.26x
ROE 0.45%
Debt
100 /100
Low Debt/Equity 0.04x
Net debt/EBITDA -0.77x
Current ratio 2.49x
Stability
57 /100
Moderate Beta 0.41x
Profitable years 6
Rev. volatility 8.33%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HNGZY
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Xiao Chun Cao
Employees
11,130
Headquarters
Hangzhou